AiVF Receives European Approval for its Cutting Edge AI based IVF Treatments

AiVF, a leader in AI technology for digitizing IVF (In Vitro Fertilization) clinics, today announced that it has received the CE Mark for use of its AI-based digital embryology management platform, EMA^TM, in IVF Fertility clinics, paving the way for use of the platform at clinics across Europe.

EMA^TM by AiVF, is a multi-module integrated platform, combines AI, computer vision, and big data to improve patients’ success rates. AiVF’s genetic evaluation tool can help determine whether a given embryo is genetically suitable for transfer without the need for an invasive biopsy (PGT-A).

“Some 30% of all IVF treatments take place in Europe, and clinics have difficulty meeting the demand for treatment,” said Daniella Gilboa, AiVF’s co-founder and CEO. “AiVF’s unique solution has created an automated lab that, through its remarkable digital capabilities, is able to perform many of the embryologist's tasks rapidly, accurately and objectively.”

AiVF currently has the largest embryo database in the world, guaranteeing high accuracy of its clinical predictions. The AiVF platform offers objective and automatic tools, and its performance has been hailed by clinicians as exceptional. The system is in use at a number of European clinics and clinical trials are also underway in the USA toward forthcoming FDA approval.

“CE approval gives us an excellent starting point to operate as one of the leading companies in the European IVF market, which is the largest in the world with more than 1 million treatments performed annually in 1200 clinics, and a market estimated at $4.5 billion,” Gilboa added. “AiVF’s solution could dramatically improve the chances of successful IVF treatments and lower their cost in the EU, thus reducing the suffering of those going through the IVF process and enabling millions of others to fulfill their dream of having a baby.”

As part of the company’s vision to streamline and improve the journey from IVF to parenthood, Prof. Dan Ariely, a world leader in the field of behavioral economics was appointed Chief Behavioral Officer. He is currently helping AiVF develop social and behavioral strategies that shape the next stage of IVF, including reproductive choices and family priorities.

AiVF was established to bring IVF into the digital age, harnessing the most innovative technologies available to revolutionize the field and help take the guesswork out of IVF. AiVF’s solution reduces the anxieties and difficulties of women going through IVF and helps close the gap between the demand for IVF treatments and the clinics’ ability to meet it. Today, in the United States a round of IVF averages $20,000, and with many women going through 5 rounds, the cost of treatment is often prohibitive. With AiVF, the chances for successful pregnancy are higher, necessitating fewer rounds and opening the dream of becoming parents to more people.

Professor Daniel Seidman, MD, co-founder and Chief Medical Officer at AiVF, noted: “Traditional embryo evaluation technique is performed manually and is not AI data driven. AiVF’s studies show remarkable accuracy, proving that a digital system can outperform an embryologist in making IVF decisions. With AiVF technology now commercially available in Europe and soon in the US, we can offer the first in class product to improve the chances of pregnancy and of delivering a healthy baby to the world.”

About AiVF
AiVF was created to help people who dream of having a child, and the doctors and clinics that support this dream. The company was founded in 2018 by Daniella Gilboa, an experienced clinical embryologist and a biostatistician and Professor Daniel Seidman, one of the busiest IVF practitioners in the world.  AiVF is made up of a team of outstanding group of AI experts, leading biologists and physicians, who created the world's most advanced digital platform for IVF fertility clinics. Special emphasis is given to the patient’s journey with the solution facilitating a shorter time to pregnancy.

AiVF is backed by private equity and by prestigious scientific grants from Israeli and European sources. The company currently employs 12 people at its R&D center in Tel Aviv.

To learn more, please visit https://aivf.co